Targeting angiogenesis has been a highly pursued strategy against MM and, in particular, blocking VEGF through bevacizumab in addition to the pemetrexed-platinum doublet improved PFS and overall survival, as assessed in the first large Phase III MAPS trial, spurring enthusiasm in the field [157,158]. The gene discussed is VEGFA; the disease is Miyoshi myopathy.